
TLX Stock Forecast & Price Target
TLX Analyst Ratings
Bulls say
Telix Pharmaceuticals is well-positioned for future growth, with a strong pipeline of potential radiopharmaceuticals, as well as its current revenue from US sales of Illuccix. The recent collaboration agreement with Regeneron Pharmaceuticals not only provides significant upfront payments but also validates Telix's R&D platform and manufacturing capabilities, further strengthening its growth potential. Risks to the company's success include potential clinical and regulatory failures, which could impact sales estimates and hinder future growth.
Bears say
Telix Pharmaceuticals is currently highly dependent on the success of its prostate cancer imaging agent, Illuccix, and has a limited track record of revenue generation. Additionally, the company faces significant risks in terms of clinical and regulatory failures with its other potential radiopharmaceuticals. While the company has a promising pipeline, it may take several years for these programs to generate significant revenue, making it a risky investment.
This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
TLX Analyst Forecast & Price Prediction
Start investing in TLX
Order type
Buy in
Order amount
Est. shares
0 shares